NAME OF APPLICANT/PHCR	: CIPLA MEDPRO (PTY) LTD.
PRODUCT PROPRIETARY NAME	: LAMISPOR 250
DOSAGE FORM	: TABLET
DOSAGE STRENGTH	: 250 mg

b) Patient information leaflet

The under-mentioned information with regard to this medicine shall appear on the patient information leaflet. The information shall be presented in the format stipulated, provided that the Council may authorise any deviation from such information or such format (refer to Regulation 10 of the Act).

1. Scheduling status
2. Proprietary name and dosage form
3. Composition of the medicine, that is, what this medicine contains
4. Approved indication and use, that is, what this medicine is used for
5. Instruction before taking the medicine
6. Instructions on how to take the medicine
7. Side effects
8. Storage and disposal information
9. Presentation
10. Identification
11. Registration number
12. Name and business address of the holder of the certificate of registration
13. Date of publication of the Patient Information Leaflet.

1. Proposed Patient Information Leaflet **1C-011**

1C-011

Patient Information Leaflet
Information for the Patient about

LAMISPOR 250 tablets

Read all of this leaflet carefully before you start taking this medicine.

- **Keep this leaflet , you may need to read it again.**
- **If you have further questions please ask your doctor or your pharmacist.**
- **This medicine has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.**

SCHEDULING STATUS:

S4 — Ref 1

PROPRIETARY NAME AND DOSAGE FORM:

LAMISPOR 250 tablets — Ref 1

WHAT LAMISPOR CONTAINS:

The active substance is terbinafine hydrochloride. LAMISPOR 250 contains 250 mg terbinafine hydrochloride. — Ref 2, Ref 1

List of excipients:

magnesium stearate, colloidal anhydrous silica, methylhydroxypropylcellulose, microcrystalline cellulose, sodium carboxymethyl starch. — Ref 2

WHAT LAMISPOR IS USED FOR:

LAMISPOR belongs to a class of drugs called Fungicides.

It is used to help control some types of Fungal infections of the skin caused by dermatophytes such as Tricophyton *(e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T.violaceum)*, *Microsporum canis and Epidermophyton floccosum*. Oral **LAMISPOR** is indicated in the treatment of ringworm (*Tineal corporis, Tinea cruris and Tinea pedis)* and yeast infections of the skin caused by Candida (e.g. Candida albicans), where oral therapy is considered appropriate owing to the site, severity or — Ref 3, Ref 1

extent of the infection. Onychomycosis (Fungal infection of the nail) caused by dermatophyte fungi.

Children: *Tinea capitis.*

Ref 1

Note: In contrast to topical **LAMISPOR**, oral **LAMISPOR** is not effective in *pityriasis versicolor* and also not in gastro-intestinal and vaginal candidiasis.

Ref 1

BEFORE YOU USE LAMISPOR :

Do not take LAMISPOR if you:

- Have shown hyper-sensitivity to terbinafine or any other components of the formulation.
- Pregnancy and lactation, as safety and efficacy has not been demonstrated. Terbinafine is excreted in breast milk, mothers breastfeeding infants should not use **LAMISPOR.**
- Impaired liver function.

Ref 1

Take special care with LAMISPOR :

The presence of other medical conditions may affect the use of **LAMISPOR.** Tell your doctor or pharmacist if you have any of the following conditions as you may require a lower dose or special monitoring;

- **Patients with alcoholism or hepatic function impairment may be at increased risk of severe hepatotoxicity. Hepatic function impairment was found to reduce the clearance of terbinafine by approximately 30%. It is recommended that patients with pre-existing stable chronic liver function impairment receive a 50% reduction in dose.**

Ref 1

If you are taking the following in addition to **LAMISPOR**, please tell your doctor or pharmacist. In certain cases, your doctor may want to change the

dose, or other precautions may be necessary:

- Cases of menstrual irregularities have been reported in patients taking LAMISPOR concomitantly with oral contraceptives. On the other hand, the plasma clearance of terbinafine may be accelerated by medicines which induce metabolism (such as rifampicin) and may be inhibited by medicines which inhibit cytochrome P-450 (such as cimetidine). Where co-administration of such agents is necessary, the dosage of **LAMISPOR** may need to be adjusted accordingly. Ref 1
- *In vitro* studies have shown however, that the terbinafine inhibits the CYP2D6-mediated metabolism. This *in vitro* finding may be of clinical relevance for compounds predominantly metabolized by this enzyme such as tricyclic antidepressants (TCAs), b-blockers, selective serotonine re-uptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs) Type B, and if they also have a narrow therapeutic window. (See special precautions for use.)
- According to the results from studies undertaken *in vitro* and in healthy volunteers, terbinafine shows negligible potential for inhibiting or enhancing the clearance of medicines that are metabolized via the cytochrome P-450 system (e.g. cyclosporine, terfenadine, triazolam, tolbutamide or oral contraceptives).

Effects on driving ability and use of machinery:

LAMISPOR has not been shown to have any effect on the ability to driving or using machinery. Ref 3

Taking LAMISPOR with food and drink:

LAMISPOR can be taken without regard to meals. Each tablet should be swallowed whole with fluid. Do not divide, crush, chew or place the tablet in water. It is recommended that tablets not be broken See **"HOW TO TAKE LAMISPOR"**. Ref 3

Use in pregnancy and breast feeding:

The safety of LAMISPOR in pregnancy and lactation has not been established.

If you are pregnant or breast feeding your baby while taking this medicine, please consult your doctor, pharmacist or other healthcare professional for advice.

Ref 1
Ref 3

Use in children:

LAMISPOR is intended for use in paediatric patients, 2 years of age and older.

Ref 1

Use in elderly:

LAMISPOR appears to pose no exceptional safety problems for healthy elderly patients. There is no evidence that elderly patients require different dosages or experience different side effects than younger patients. When prescribing for patients in this age group, the possibility of pre-existing impairment of liver or kidney function should be considered.

Ref 1

Taking other medicines with LAMISPOR?

See **"BEFORE YOU TAKE LAMISPOR "**

If you are taking other medicines on a regular basis, use of this medicine with other medicines may cause undesirable interactions.

Ref 3

Please consult your doctor or pharmacist.

HOW TO TAKE LAMISPOR :

Always take LAMISPOR exactly as your doctor has instructed you.

You should check with your doctor or pharmacist if you are unsure.

Ref 3

The dose of **LAMISPOR** will be different for different patients.

1C-015

Adults:

Take one 125 mg tablet twice a day or one 250 mg once a day.

Skin infections: Recommended duration of treatment:

Tinea pedis (interdigital, plantar/ moccasin type):	2 to 6 weeks
Tinea corposis, cruris:	2 to 4 weeks
Cutaneous candidiasis:	2 to 4 weeks

Ref 1

Complete resolution of the signs and symptoms of infection may not occur until several weeks after mycological cure.

Hair and scalp infections: Recommended duration of treatment:

Tinea capitis:	4 weeks

Tinea capitis occurs primarily in children.

Onychomycosis:

For most patients, the duration of successful treatment is 6 to 12 weeks. Treatment periods of less than 3 months can be anticipated for patients with fingernail infection, toenail infection other than of big toenail, and in patients of a younger age. In the treatment of toenail infections, 3 months is usually sufficient, although a few patients may require treatment of 6 months or longer. Poor nail outgrowth during the first weeks of treatment may enable identification of those patients in whom longer therapy is required. In fungal nail infections, the optimal clinical effect is seen some months after mycological cure and cessation of treatment. This is related to the period required for outgrowth of healthy nail tissue. Limited experience is available for periods longer than 6 months.

Ref 1

Hepatic and renal impairment: Patients with impaired renal function (creatinine clearance less than 50 ml/min or serum creatinine of more than 300 umol/l) should have their dose halved, i.e. 125 mg once daily or 62,5 mg twice daily.

Ref 1

Children:

Children (*with Tinea capitis*): No data are available in children under 2 years of age (*usually* less than 12 kg).

Children weighing under 20 kg: 62,5 mg (half a 125 mg tablet) once daily

Ref 1

Children weighing 20 to 40 kg: 125 mg (one 125 mg tablet) once daily
Children weighing more than 40 kg: 250 mg (two 125 mg tablet) once daily

Ref 1

Please consult your doctor before abruptly discontinuing LAMISPOR as your doctor will advise you on the tapered dose to minimise the risk of discontinuation symptoms.

If you take more LAMISPOR than you should:

In the event of an overdosage (if you take too many tablets), or if someone else has taken your medicine by mistake, the stomach should be emptied immediately by lavage or vomiting or contact your doctor or pharmacist **immediately.** If neither is available, seek help at the nearest hospital or poison control centre where you or the other person involved will receive supportive treatment.

Ref 3

If you forget to take LAMISPOR

Take LAMISPOR as prescribed. If you miss a dose of this medicine, take it as soon as possible. However, if you do not remember the missed dose until the next day, skip the missed dose and go back to your regular dosing schedule. Do not take a double dose to compensate for the forgotten individual dose.

Ref 3

POSSIBLE SIDE-EFFECTS:

What undesirable effects may LAMISPOR have?

- LAMISPOR can have side-effects. As with any medicine, LAMISPOR may have unintended or undesirable effects.
- The most frequently observed adverse effects are:

Feeling of fullness, loss of appetite, dyspepsia, arthralgia, myalgia, cholestatic liver dysfunction, skin rash, urticaria. Ref 1

- The occurrence of many frequently observed adverse events is dose related. These generally decrease in intensity and frequency with continued therapy. Check with your doctor as soon as possible if the side-effects persist and become bothersome. Ref 3

The following side-effects have been reported (≥ 1 % of patients):

Gastrointestinal:

Frequent:	Feeling of fullness, loss of appetite, dyspepsia,
Less Frequent:	Taste disturbances, including taste loss, which usually recover within several weeks of discontinuation of the drug.

Ref 1

Musculoskeletal:

Frequent:	Arthralgia, myalgia

Haematologic/Lymphatic:

Less Frequent:	neutropenia, agranulocytosis or thrombocytopenia

Ref 1

Hypersensitivity Reactions:

Frequent:	Skin rash, urticaria
Less Frequent:	serious skin reactions (e.g. Stevens-Jonson syndrome, toxic epidermal necrolysis) and anaphylactoid reaction have been reported.

If progressive skin rash occurs, LAMISPOR treatment should be discontinued.

Other:

Less Frequent:	Hair loss has been reported, although a casual relationship has not been established.

Ref 3

Not all side-effects reported for this medicine are included in this leaflet. Should your general health worsen while taking this medicine, please consult your doctor, pharmacist or other healthcare professional for advice.

STORAGE AND DISPOSING OF LAMISPOR: Ref 1

Store this medicine out of reach of children.

Store below 25°C. Protect from light.

Keep the blister strips in the outer carton until required for use. Ref 3

Do not use after the expiry date stated on the packaging material.

Return all unused medicine to your pharmacist.

Do not dispose of unused medicine in drains or sewerage systems, for example toilets.

PRESENTATION OF LAMISPOR: Ref 1

LAMISPOR 250: Supplied in white opaque PVC and aluminium foil blister strips of 14 tablets.

IDENTIFICATION OF LAMISPOR : Ref 1

LAMISPOR 250: White, circular, biconvex uncoated tablet, with deep score on one side and plain on the other side. Ref 1

REGISTRATION NUMBER:

To be allocated.

1C-019

NAME AND BUSINESS ADDRESS OF THE HOLDER CERTIFICATE OF REGISTRATION:

Ref 1

CIPLA MEDPRO (PTY) LTD

Rosen Heights

Pasita Street

Rosen Park, Bellville

7530

Ref 1

DATE OF PUBLICATION OF THIS PATIENT LEAFLET:

1C-020

REFERENCES TO PATIENT INFORMATION LEAFLET

REFERENCES	MRF1 PAGES
1. Proposed PI submitted by CIPLA MEDPRO (PTY) LTD	1C-002
2. MRF 1, Part 3B – Formulation	3B-001
3. Guideline on the requirements for patient information leaflets, May 2004	1C-021

PATIENT INFORMATION LEAFLET
[Heading to be printed]

[For medicinal products available only on prescription]
<Read all of this leaflet carefully before you start <taking> <using> this medicine>

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor or your pharmacist.
- This medicine has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.>

[For medicinal products available without a prescription]
<Read all of this leaflet carefully because it contains important information for you
This medicine is available without a doctor's prescription, for you to treat a mild illness. Nevertheless you still need to use X carefully to get the best results from it.

- Keep this leaflet. You may need to read it again.
- Ask your pharmacist if you need more information or advice.
- You must see a doctor if your symptoms worsen or do not improve after *[number of]* days.>

[Scheduling status of the medicinal product]
[The Scheduling status of the product as prescribed in the Schedules to the Act should be included here]

[Name of the medicinal product]
{(Proprietary) name, strength and pharmaceutical form}
{Active substance}
[The (proprietary) name of the medicinal product (referred to as X throughout this document) should be stated here in bold, followed by the strength and pharmaceutical form (i.e. as it appears in the professional Package Insert). This should be followed by the INN or common name of the active substance (as stated on the label), which may be written on the line below.]

1. WHAT X CONTAINS

[Full statement of the active substance(s) and excipient(s)]
[The active substance(s) (expressed qualitatively and quantitatively) and the other ingredients (expressed qualitatively) should be identified using their names as given in the professional Package Insert and in the language of the text: e.g.]

- The active substance is...
- The other ingredients are... *[These should be listed in a single alphabetical list. If a preservative or alcohol (2% or more) is present, the content of each must be indicated]*

2. WHAT X IS USED FOR

[Pharmacotherapeutic group]
[The pharmacotherapeutic group or type of activity should be stated here using language understandable to the patient]
[Therapeutic indications]
[The registered indications for use of the medicine, as accepted by Council, should be stated here, using language understandable to the patient. If appropriate, the following may be specified:]
<This medicinal product is for diagnostic use only.>

3. BEFORE YOU <TAKE> <USE> X

[List of information necessary before taking the medicinal product]
[This section must take into account the particular condition of certain categories of users, e.g. children and the elderly (specify the age range, special patient populations, e.g. patients with renal or hepatic impairment.]

[Absolute contraindications]
Do not <take> <use> X:

- <if you are hypersensitive (allergic) to *{active substance}* or any of the other ingredients of X.> *[include reference to residues, excipients, etc, if applicable]*
- <if you ...>

[Information on absolute contraindications, in accordance with the professional Package Insert, should be provided here. This should be in patient understandable language and should be strictly limited to contraindications, including chronic accompanying diseases and contraindications due to interactions with other medicinal products. Other precautions and special warnings should be made in the following subsection.]

[Appropriate precautions for use, special warnings]
Take special care with X:

- <if you ...>
- <when ...>

[Information, in patient-friendly language, on relative contraindications, special warning and appropriate precautions for use should be provided here. Include information on interactions with other medicinal products]

[Interactions with food and drink]
<Taking > <Using> X with food and drink:

[Use by pregnant or breast-feeding women]
Pregnancy and Breast-feeding
[Include information given in the professional Package Insert, in patient-friendly language. The following additional statement must be included:]
<If you are pregnant or breast feeding your baby while taking this medicine, please consult your doctor, pharmacist or other health care professional for advice.>

[Effect on the ability to drive or use machinery]
Driving and using machinery:
<Do not <drive because...>
<Do not operate any tools or machines.>
[Excipient warnings]
Important information about some of the ingredients of X:
[If appropriate, details of those excipients knowledge of which is important for the safe and effective use of the medicinal product]

[Interaction with other medicinal products]
Taking> <Using other medicines with X:
[The following statement must be included:]
<If you are taking other medicines on a regular basis, including complementary or traditional medicines, the use of X with these medicines may cause undesirable interactions. Please consult your doctor, pharmacist or other healthcare professional, for advice.>

4. HOW TO <TAKE> <USE> X

[Instructions for proper use]

[The following 4 items can be combined as one paragraph]

[Dosage]
[The recommended dosage should be included here. The following statements should be included, where applicable:]
<Always take X exactly as your doctor has instructed you. You should check with your doctor or pharmacist if you are unsure.> <The usual dose is...>

<If you have the impression that the effect of X is too strong or too weak, talk to your doctor or pharmacist.>

[Method and/or route(s) of administration]
[Method of administration: directions for the proper use of the medicinal product; e.g.:]
'Do not swallow',
'Do not chew',
'Shake well before use',
'Allow to reach room temperature before using' *[e.g. insulins]*
[Route(s) of administration must be indicated in patient understandable language]

[Frequency of administration]
[Specify if necessary the appropriate time at which the medicinal product may or must be administered]

[Duration of treatment]
[Specify in which cases it should be limited]

[Symptoms in case of overdosage and actions to be take]
If you <take> <use> more X than you should:
[Description of signs and symptoms of overdosage that the patient is able to recognize and actions to be taken]
[The following statement must be included:]
<In the event of overdosage, consult your doctor or pharmacist. If neither is available, seek help at the nearest hospital or poison control center.>

[Actions to be taken when one or more doses have been missed]
If you forget to take X:
[Provide clear explanations of what should be done following irregular use of the medicinal product, e.g.:]
<Do not take a double dose to make up for forgotten individual doses.>

[Indication of the risk of withdrawal effects]
Effects when treatment with X is stopped:
[Indicate any effects of interruption or ending treatment early, if applicable. Indicate withdrawal effects when the treatment ends, if applicable]

5. POSSIBLE SIDE EFFECTS

[A description of side effects should be provided. Begin this section with:]
<X can have side effects.>

[Describe, if necessary, the actions to be taken. If the patient needs to seek help urgently use the term <immediately>; *for less urgent conditions use the phrase* <as soon as possible>.*]*

[The following statement must be included:]
<Not all side effects reported for this medicine are included in this leaflet. Should your general health worsen while taking this medicine, please consult your doctor, pharmacist or other health care professional for advice.>

6. STORING AND DISPOSING OF X

[Storage conditions and disposal of unused medicine]
[The following statement must be included in this section:]
Keep all medicines out of the reach and sight of children.

[Where applicable, the following statements may be included:]
<Do not store above <25°C> <30°C>> *[Explain ideal storage environment]*
<Store at 2°C – 8°C (in a refrigerator)>
<Store in a freezer>
<Do not <refrigerate> <or> <freeze>>
<Store in the original <package> <container>>
<Keep the container in the outer carton>
<Keep the container tightly closed>
<There are no special storage instructions>

[An additional short explanation of the storage conditions, in patient-friendly terms, should be included when appropriate, e.g.:]
<in order to protect from <light> <moisture>>
<Do not store in bathrooms>
<Do not use after the expiry date stated on the <label> <carton> <bottle> <...>>

[Where applicable, shelf life after reconstitution, dilution or after first opening the container should be indicated]

[Where appropriate, warning against any visible signs of deterioration]
<Do not use X if you notice {description of the visible signs of deterioration}.>

[Information on how to dispose of unused medicine, e.g.:]
<Return all unused medicine to your pharmacist.>
<Do not dispose of unused medicine in drains or sewerage systems (e.g. toilets)>

7. PRESENTATION OF X

[In accordance with information provided in the Package Insert, including the pharmaceutical form, the number, volume or mass per package unit, pack size and a description of the packaging material, e.g. bottle, blister pack, etc.]

8. IDENTIFICATION OF X

[A physical description, e.g. shape, colour, texture, imprint, etc, of the dosage form should be included here in accordance with the Package Insert Information.]

9. REGISTRATION NUMBER/REFERENCE NUMBER

[As in the Package Insert and in accordance with Section 15 of the Act.]

10. NAME AND ADDRESS OF REGISTRATION HOLDER

[As in the Package Insert]

11. DATE OF PUBLICATION

[As in the Package Insert]